These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28216404)

  • 41. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
    Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
    ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful treatment of switching from benzodiazepine to orexin receptor antagonists improves cognitive function in psychiatric disorders: four case reports.
    Hori H
    Int Clin Psychopharmacol; 2023 May; 38(3):192-194. PubMed ID: 36539372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prescription Drugs Used in Insomnia.
    Dujardin S; Pijpers A; Pevernagie D
    Sleep Med Clin; 2020 Jun; 15(2):133-145. PubMed ID: 32386689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Orexin antagonists for insomnia.
    Young J; Lee E; Lindblad AJ; Falk J
    Can Fam Physician; 2024 Mar; 70(3):183-184. PubMed ID: 38499379
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
    Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
    Coleman PJ; Cox CD; Roecker AJ
    Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
    Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
    ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of an Orexin-2 Receptor Antagonist on Sleep and Event-Related Oscillations in Female Rats Exposed to Chronic Intermittent Ethanol During Adolescence.
    Amodeo LR; Wills DN; Sanchez-Alavez M; Ehlers CL
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1378-1388. PubMed ID: 32424852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
    Koebisu M; Koyama N; Nishida M; Muramoto K
    Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The orexin story and orexin receptor antagonists for the treatment of insomnia.
    Muehlan C; Roch C; Vaillant C; Dingemanse J
    J Sleep Res; 2023 Dec; 32(6):e13902. PubMed ID: 37086045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
    Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N
    Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of New Transmitter Systems and Hence New Drug Targets.
    Schwasinger-Schmidt T; Preskorn SH
    Adv Neurobiol; 2023; 30():181-193. PubMed ID: 36928850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
    Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
    J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.
    Roch C; Bergamini G; Steiner MA; Clozel M
    Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).
    Boss C; Roch C
    Expert Opin Ther Pat; 2016; 26(3):409-15. PubMed ID: 26593218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.
    Brotschi C; Bolli MH; Gatfield J; Heidmann B; Jenck F; Roch C; Sifferlen T; Treiber A; Williams JT; Boss C
    ChemMedChem; 2020 Mar; 15(5):430-448. PubMed ID: 31945272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.
    Yoshida Y; Terauchi T; Naoe Y; Kazuta Y; Ozaki F; Beuckmann CT; Nakagawa M; Suzuki M; Kushida I; Takenaka O; Ueno T; Yonaga M
    Bioorg Med Chem; 2014 Nov; 22(21):6071-88. PubMed ID: 25267004
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
    Hamuro A; Honda M; Wakaura Y
    Aust N Z J Psychiatry; 2018 Feb; 52(2):207-208. PubMed ID: 29237271
    [No Abstract]   [Full Text] [Related]  

  • 60. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.